Patient characteristics at baseline (tumor board decision)
| . | CAR T cells, n (%) (n = 41) . | alloHCT, n (%) (n = 60) . | P . |
|---|---|---|---|
| Age, y | .093 | ||
| Median | 55 | 51 | |
| Range | 20-73 | 19-69 | |
| Male sex | 31 (76) | 43 (72) | .82 |
| Diagnosis | .099 (DLBCL vs other) | ||
| DLBCL | 30 (73) | 34 (57) | |
| tFL | 4 (10) | 18 (30) | |
| PMBCL | 4 (10) | 2 (3) | |
| HGBCL-DH | 2 (5) | 3 (5) | |
| Other | 1 (2)* | 3 (5)† | |
| Stage III/IV at diagnosis | 27 (66) | 47 (78) | .18 |
| Type of first-line failure | .0044 (primary refractory vs other) | ||
| Primary refractory | 25 (61) | 19 (32) | |
| Early relapse (7-12 mo from start of first line) | 10 (24) | 22 (37) | |
| Late relapse | 6 (15) | 19 (32) | |
| Time from diagnosis, mo | .54 | ||
| Median | 12 | 16 | |
| Range | 4-207 | 2-231 | |
| No. of failed lines | <.0001 (1 vs >1) | ||
| Median | 2 | 2 | |
| Range | 2-7 | 1-7 | |
| 1 | 0 | 21 | |
| 2 | 21 | 23 | |
| >2 | 20 | 16 | |
| AutoHCT failure | 9 (22) | 26 (43) | .034 |
| Alternate CI failure | 4 (10) | 3 (5) | |
| HCT comorbidity index | 1.0 (0 vs >0) | ||
| 0 | 24 (59) | 34 (57) | |
| 1-2 | 8 (20) | 14 (23) | |
| >2 | 9 (22) | 12 (20) | |
| PS ≥2 | 8 (20) | 6 (10) | .24 |
| sIPI high intermediate/high | 23 (56) | 25/57 (44) | .31 |
| Bulk >10 cm | 8/40 (20) | 3/56 (5) | .047 |
| ZUMA-1 ineligible‡ | 30 (73) | 34/57 (60) | .20 |
| Rapid progression | 20 | 13 | |
| PS >1 | 7 | 5 | |
| Prior alloHCT/CAR T cells | 4 | 3 | |
| 2nd neoplasm | 1 | 4 | |
| CNS involvement | 1 | 8 | |
| Other | 4 | 5 | |
| Disease status | .39 | ||
| PD | 38 (93) | 58 (97) | |
| SD | 3 (7) | 0 | |
| CR/PR | 0 | 2 (3) | |
| Not proceeding to CI | 11 (27) | 21 (35) | .51 |
| PD | 7 | 14 | |
| Fatal infection | 2 | 1 | |
| No product/donor | 1 | 3 | |
| Refused | 1 | 1 | |
| AutoHCT | 0 | 2 | |
| Calendar year of study entry | |||
| Median | 2019 | 2014 | |
| Range | 2018-2020 | 2004-2019 | |
| Follow-up, mo | |||
| Median | 10 | 64 | |
| Range | 5-19 | 10-181 |
| . | CAR T cells, n (%) (n = 41) . | alloHCT, n (%) (n = 60) . | P . |
|---|---|---|---|
| Age, y | .093 | ||
| Median | 55 | 51 | |
| Range | 20-73 | 19-69 | |
| Male sex | 31 (76) | 43 (72) | .82 |
| Diagnosis | .099 (DLBCL vs other) | ||
| DLBCL | 30 (73) | 34 (57) | |
| tFL | 4 (10) | 18 (30) | |
| PMBCL | 4 (10) | 2 (3) | |
| HGBCL-DH | 2 (5) | 3 (5) | |
| Other | 1 (2)* | 3 (5)† | |
| Stage III/IV at diagnosis | 27 (66) | 47 (78) | .18 |
| Type of first-line failure | .0044 (primary refractory vs other) | ||
| Primary refractory | 25 (61) | 19 (32) | |
| Early relapse (7-12 mo from start of first line) | 10 (24) | 22 (37) | |
| Late relapse | 6 (15) | 19 (32) | |
| Time from diagnosis, mo | .54 | ||
| Median | 12 | 16 | |
| Range | 4-207 | 2-231 | |
| No. of failed lines | <.0001 (1 vs >1) | ||
| Median | 2 | 2 | |
| Range | 2-7 | 1-7 | |
| 1 | 0 | 21 | |
| 2 | 21 | 23 | |
| >2 | 20 | 16 | |
| AutoHCT failure | 9 (22) | 26 (43) | .034 |
| Alternate CI failure | 4 (10) | 3 (5) | |
| HCT comorbidity index | 1.0 (0 vs >0) | ||
| 0 | 24 (59) | 34 (57) | |
| 1-2 | 8 (20) | 14 (23) | |
| >2 | 9 (22) | 12 (20) | |
| PS ≥2 | 8 (20) | 6 (10) | .24 |
| sIPI high intermediate/high | 23 (56) | 25/57 (44) | .31 |
| Bulk >10 cm | 8/40 (20) | 3/56 (5) | .047 |
| ZUMA-1 ineligible‡ | 30 (73) | 34/57 (60) | .20 |
| Rapid progression | 20 | 13 | |
| PS >1 | 7 | 5 | |
| Prior alloHCT/CAR T cells | 4 | 3 | |
| 2nd neoplasm | 1 | 4 | |
| CNS involvement | 1 | 8 | |
| Other | 4 | 5 | |
| Disease status | .39 | ||
| PD | 38 (93) | 58 (97) | |
| SD | 3 (7) | 0 | |
| CR/PR | 0 | 2 (3) | |
| Not proceeding to CI | 11 (27) | 21 (35) | .51 |
| PD | 7 | 14 | |
| Fatal infection | 2 | 1 | |
| No product/donor | 1 | 3 | |
| Refused | 1 | 1 | |
| AutoHCT | 0 | 2 | |
| Calendar year of study entry | |||
| Median | 2019 | 2014 | |
| Range | 2018-2020 | 2004-2019 | |
| Follow-up, mo | |||
| Median | 10 | 64 | |
| Range | 5-19 | 10-181 |
CNS, central nervous system; HGBCL-DH, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements/double-hit lymphoma; PD, progressive disease; SD, stable disease; sIPI, secondary International Prognostic Index; tFL, transformed follicular lymphoma.
DLBCL: leg type.
DLBCL: transformed from marginal zone lymphoma (n = 2), Gray zone lymphoma (n = 1).
Disregarding n of failed lines.